In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Spanish skincare specialist Almirall has announced positive results from a real-world study of Ilumetri (tildrakizumab) at the 25th World Congress of Dermatology. 7 July 2023
Biotechnology
US pharma giant Pfizer has made a $25 million equity investment in Caribou Biosciences, a Californian CRISPR genome-editing company. 7 July 2023
Biosimilars
Indian drugmaker Biocon says that its subsidiary Biocon Biologics has completed the integration of the acquired biosimilars business in over 70 countries in emerging markets effective July 1, 2023, ahead of schedule, increasing the scale and scope of its business. 7 July 2023
Pharmaceutical
Privately-held Italian drugmaker Chiesi Farmaceutici has appointed Alessandro Chiesi as chairman of the Chiesi Group. Additionally, it said that Maria Paola Chiesi becomes vice chair. 7 July 2023
Biotechnology
New Jersey, USA-based oncology company Hillstream BioPharma has signed an exclusive collaboration agreement with the Applied Biomedical Science Institute (ABSI). 7 July 2023
Pharmaceutical
Shares of US clinical-stage drug developer Histogen rocketed 33% to $$0.97 in after-hours trading yesterday, after it indicated that the company could be up for sale. 7 July 2023
Biotechnology
Shares in Singapore and California-based biotech ASLAN Pharmaceuticals have fallen by a quarter as traders pore over mid-stage data for lead candidate eblasakimab. 7 July 2023
Pharmaceutical
The European Medicines Agency (EMA), the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the extraordinary regulatory flexibilities for medicines put in place during the COVID-19 pandemic to help address regulatory and supply challenges arising from the pandemic. 7 July 2023
Pharmaceutical
Big pharma companies Novartis and Eli Lilly announced major deals during a big-spending month in mergers and acquisitions. 6 July 2023
Pharmaceutical
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced that it has sharpened its strategic focus on the development of novel, therapeutic candidates for the prevention and treatment of moderate to severe and 6 July 2023
Pharmaceutical
The UK-based non-profit medical research organization and charity LifeArc has announced a program to invest more than £100 million ($127 million) by 2030 to deliver new breakthroughs in rare diseases. 6 July 2023
Pharmaceutical
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, today announced it has entered into a licensing agreement and strategic partnership with a UK-based innovative drug development and manufacturing company. 6 July 2023
Biotechnology
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress with the deputy chief clinical officer of the firm's American business. 6 July 2023
Biotechnology
Jacobio Pharmaceuticals Group closed 16% lower following Thursday’s trading in Hong Kong. 6 July 2023
Pharmaceutical
The Foreign Direct Investment (FDI) equity inflow into the pharmaceutical industry in India has jumped by 45.4% in the fiscal year ended March 2023, compared to inflow in the previous fiscal year. 6 July 2023
Biotechnology
US protein-based vaccine developer Novavax saw its shares fall more than 4% to $7.06, despite announcing it has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for Nuvaxovid (NVX-CoV2373). 6 July 2023
Biotechnology
Ryvu Therapeutics, Poland’s largest biotech firm, said today it has signed two agreements with Zakłady Farmaceutyczne Polpharma relating to its lead candidate RVU120 active pharmaceutical ingredient (API) production for Phase II clinical studies in hematology: RIVER-52 and RIVER-81. 6 July 2023
Biotechnology
A new kind of antibody developed by Japan’s Astellas Pharma will be considered for approval in the USA under the Priority Review scheme. 6 July 2023
Biotechnology
Shares of US biotech Moderna, which is pioneering messenger RNA (mRNA) therapeutics and vaccines, edged up 1.5% to $123.54 yesterday, as it updated on regulatory submissions for mRNA-1345. 6 July 2023
Biotechnology
A new partnership will see nanomedicine-focused contract development and manufacturing organization (CDMO) Ardena join forces with Dutch company RiboPro. 6 July 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze